Latest Regulatory Scrutiny News

EMC Gold has withdrawn its Salave Gold Project’s strategic interest application to strengthen future submissions, while raising €2.64 million from Spanish investors to advance engineering work.

ECS Botanics Holdings Ltd has seen its ECSO securities suspended from ASX quotation due to non-compliance with listing rules, raising questions about the company’s next steps.

Macquarie Asset Management has extended the exclusivity period for its proposed transaction with Qube Holdings, signalling ongoing progress yet leaving the final outcome uncertain.

Critica Limited has addressed a recent spike in its share price and trading volume, attributing the movement to positive research coverage while confirming no undisclosed information is driving the activity.

Invictus Energy has ended its strategic partnership and equity investment agreement with Al Mansour Holdings due to irreconcilable differences and regulatory concerns. The company now refocuses on its core Zimbabwean assets while seeking alternative funding.

Novo Resources has responded to an ASX price query, attributing recent share price and volume spikes to insider buying and rising gold prices, while confirming no undisclosed material information.

N1 Holdings Limited has reported a strong December quarter with rising revenue, net profit, and cash receipts, underpinned by SME lending growth and funding efficiency improvements. The company also navigates increased regulatory scrutiny with a firm commitment to conservative lending.

The Australian Competition and Consumer Commission has advanced its review of Ampol’s acquisition of EG Australia to a more detailed Phase 2 assessment, signalling potential competition concerns. Ampol remains optimistic about completing the deal by mid-2026 despite the regulatory scrutiny.

Richmond Vanadium Technology Limited has responded to an ASX price query following a sharp rise in its share price and trading volume, confirming no undisclosed information is driving the activity and attributing the surge to broader market interest and improved liquidity.

Astron Limited has responded to an ASX query regarding delayed disclosure of director interest changes, attributing the lapse to administrative oversight and outlining steps to tighten compliance.

Aristocrat Leisure and Light & Wonder have resolved their high-profile intellectual property litigation with a $190 million settlement and the withdrawal of disputed games from the market.

Pharmaceutical manufacturer ANO has been hit with a US FDA Import Alert, joining several Australian peers amid wider regulatory tensions. The company is mobilising expert consultants and preparing a petition to lift the alert within weeks.